Rearch homepage new banner Nov 2013

AstraZeneca is a global biopharmaceutical company with research and development at its core

Our expertise research and development spans the entire life-cycle of a medicine. We have capabilities in both small molecules and biologics. This allows us to search for solutions to unmet medical needs using both modalities, individually or in combination


Heptares and AstraZeneca: Combining forces in novel approach to drug discovery

An IMED Collaboration Update

When AstraZeneca was looking for alternative approaches to finding compounds for some particularly difficult targets, we teamed up with UK biotech Heptares Therapeutics. Heptares uses its proprietary Stabilised Receptor or StaR® technology to enable the techniques of structure-based and fragment-based drug discovery to be applied to difficult GPCR targets that our scientists have nominated. By combining our expertise, technologies and capabilities, this collaboration allows for a novel way of finding hits that we would otherwise not have been able to do, in order to bring new medicines to people who need them.

Download collaboration update (PDF 337kb)


View more collaboration updates
 


Our leaders iconOur leaders

All Directors are collectively responsible for the success of AstraZeneca. Discover general information,  images and biographies of our Board of Directors.

Read more


Pipeline iconOur pipeline

AstraZeneca's pipeline is one of the most exciting in the industry. Download the latest version of our development pipeline.

Read more


Path to meds iconPath to new medicines

The discovery, development and commercialisation of a medicine is a complex process. Information on our path to new medicines and an interactive overview are available.

Read more


Neuro iconAZ Neuroscience

Visit our dedicated neuroscience site for more information on our research and partnering in the area.

 

Visit site


Open innovation iconOpen innovation

Visit our Open Innovation site to see how we collaborate to push the boundaries of science and deliver life-changing medicines

Visit site


LabTalk is AstraZeneca’s science-focused blog where you can hear from scientists, researchers and academics discussing novel ideas, research and innovation.

AZ_Science_strategies_THM 22 January 2015

AstraZeneca science strategies in emerging innovation clusters

The_PARP_THM 19 December 2014

The PARP inhibitor paradigm: a collaborative approach to cancer drug discovery

Targeting_escape_THM 10 December 2014

Targeting escape pathways to further personalise breast cancer treatment